Welcome to Beacon Equity Research. Today is Friday, 17 August 2007  
 Home     Covered Companies     News and Commentary     Our Team     Ratings     Resources     Contact Us    
BioStem, Inc. (OTCBB: BTEM)
Untitled Document
Fill out the form below to get regular information updates on BTEM and other stocks.

BioStem, Inc.
200 Hannover Park Road
Suite #120
Atlanta, GA 30350
United States of America

Tel: (770) 650 1733
BioStem, Inc. (OTCBB: BTEM) is in the process of acquiring Cryobanks International Inc. (CII). CII is a leader in the collection, processing, and banking of stem cells derived from the umbilical cord (CBSCs) immediately after birth. The units of cord blood (CB) are processed and stored at CII for use in unrelated transplants (where the donor is a likely compatible match, but is anonymous and unrelated to the recipient) and for personal storage and use.
Other stocks such as Viacell (VIAC), Cryo-Cell (CCYL) and Stemcells (STEM) have yielded huge gains for early investors. BioStem (BTEM) is aggressively growing its business and may prove to be an even bigger winner once the investment community catches on.
Cryobanks International, is a pioneer in the collection, isolation, and storage technologies for cord blood stem cells. Its mission is to become the largest provider of cord blood stem cells for transplant and research purposes in the world.
Based on company estimates, demand may be as many as 35,000 transplant requests per year in the U.S. alone. Cryobanks International is well poised to help meet that need, equipped with an inventory of over 9,000 (CB) cord blood units.
The Company has 10 licensed affiliates operational high growth locations like Athens, Greece and New Delhi, India with construction underway at the United Arab Emirates (UAE) location and newly signed Bangkok location. Seven to six additional locations are planned to open in India over the course of the next 36 months. Additionally, CII projects more than 40 locations scheduled to open worldwide over the next few years.
Cryobanks International, Inc., which is to be acquired by BioStem, Inc. announced that upon the completion of the $9.0 million funding announced on March 14, 2007, Biostem intends to file an application to list BioStem, Inc. on the American Stock Exchange with the hope that the AMEX listing will become effective upon the closing of the merger.

Biostem Inc. (OTCBB: BTEM), changed its name to BioStem in November 2005, the Board of Directors actively sought a merger with a privately held company in the cord blood banking business. On November 22, 2005, BioStem Inc. agreed to merge with Cryobanks International, Inc. Prior to this merger, BioStem had limited operations focused mainly on parking and parking related services. Upon closing of the merger, these subsidiaries will be divested from BTEM, and Cryobanks will be the only remaining entity.
Cryobanks International, Inc., a pioneer in the collection, isolation, and storage technologies for cord blood stem cells. Cryobanks International Inc. (CII), located in Altamonte Springs Florida, is engaged in the collection, processing, and cryogenic cellular storage of umbilical cord blood stem cells from non-related donors, for personal or sibling use, and for research purposes.
The company was founded in 1993 in Altamonte Springs, Florida, which is a suburb of Orlando, and has a growing inventory of over 9,700 CBUs for future use in transplants and medical research. Cryobanks International, initially formed as a semen bank and a clinical and andrology laboratory, expanded its scope of business into the field of cord blood banking in mid-1995. The company is focused on providing high-quality umbilical cord blood stem cell processing, and storage for both private family use and public donation purposes. Cryobanks International was incorporated as a Delaware corporation in May 1999 as an umbilical cord blood stem cell collecting, processing & storage enterprise, processing both personal and donated cord blood for use in transplantation & research.
CII established the first and only nationwide system for donating cord blood. Since 1995, Cryobanks International, Inc. (CII) has been accepting and processing donated cord blood units from anywhere in the United States. It is the only facility accepting donated cord blood units from anywhere in the continental U.S., every day of the week 24 hours per day. Fully accredited by the American Association of Blood Banks (AABB) and a member of the National Marrow Donor Program® Cord Blood Bank Network (NMDP), CII processes donated units following the highest standards in the industry and is a licensed PharmaStem cord blood bank. Units that qualify are listed on international registries so that anyone in need of a potential life-saving stem cell transplant may find an acceptable match. Cryobanks is New York and New Jersey State licensed, and is FDA registered.
The Closing of the merger between Cryobanks and Biostem is subject to certain contingencies more fully described in Current Form 8-K filed November 28, 2005 with the SEC. According to the terms of the merger with Cryobanks, BioStem must restructure its capitalization by canceling certain shares held by former shareholders, and potentially effecting a reverse split of its common stock, and must reduce its debt to under $25,000 in accrued liabilities. In addition, Cryobanks must successfully raise at least $10,000,000 in a private placement offering. The offering was planned is for preferred stock at $1.00 per share with warrants to purchase 3,000,000 shares of Cryobanks
common stock, exercisable at $1.10 per share. Upon closing of the merger, BTEM will divest its two operating subsidiaries, issue 120,000,000 shares of common stock or an approximately 88% majority to Cryobanks shareholders. Additional terms of the merger calls for the current management of BioStem to resign, and the Board of Cryobanks to assume control of the company. The closing date was recently extended and now specifies that the merger must be completed by June 30th, 2007 or the letter of intent will expire. BioStem anticipates that the merger will be extended again to allow time for the $9.0 million financing to close, although there is no assurance that this will happen.
The company is focused on four lines of business all related to collection and storage of cord blood stem cells:
i. Umbilical Cord Donation: Anonymous donor CBUs for unrelated cord blood transplants,
ii. Umbilical Cord Research,
iii. Umbilical Cord Storage: Personal cord blood storage for possible future use by the family, and
iv. Licensing of Proprietary Standard Operating Procedures: The licensing of the company's proprietary process for setting up and operating a cryogenic storage facility.
The company has also partnered with research institutions that are developing stem cell based therapies to treat disease. The Company has processed over 15,000 units of cord blood to date. Its first licensed facility opened in Athens Greece in December 2005. Its second licensed facility opened in Delhi, India in October 2006. Cryobanks occupies a modern state-of-the-art facility of approximately 6,200 square feet and has 19 employees. The Company has a well-established Business Board, and an active Scientific and Medical Board of Advisors (S.A.M.B.A.).
Name Email
Phone Fax
Address City
States Zip/Postal Code
= Required
[ Back ]

Fill out the form to
get regular FREE
information updates
on this and other stocks.







Copyright 2007 Beacon Equity Research